{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:38Z","timestamp":1787009918585,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To conduct a cost analysis of adjunctive hydrocortisone therapy for severe septic shock from the perspective of a third-party payer in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Estimates of outcomes were aggregate data from the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids for Human Septic Shock trials. In these trials, the outcomes of interests were ICU length of stay, vasopressor-free days, ventilation-free days, and the proportion of patients receiving blood transfusion. Each outcome was monetized into a set of mutually exclusive components and was aggregated to estimate the cost-per-patient based on each trial. Cost inputs for each outcome were obtained from literature and adjusted based on the medical care consumer price index. To estimate the budget impact using adjunctive hydrocortisone therapy, per-patient avoided cost was multiplied by expected septic shock annual incidence. Deterministic one-way sensitivity analysis evaluated the robustness of the findings, and Monte Carlo simulation estimated 95% CI of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>A total of 103 medical-surgical ICU (69 for Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock and 34 for Activated Protein C and Corticosteroids for Human Septic Shock).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients:<\/jats:title>\n                    <jats:p>Adults greater than or equal to 18 years old with septic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Adjunctive hydrocortisone therapy (hydrocortisone at a dose of 200\u2009mg\/d for 7 d for Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock and hydrocortisone at a 50\u2009mg IV bolus every 6\u2009hr and fludrocortisone as a 50 \u03bcg tablet once daily).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results:<\/jats:title>\n                    <jats:p>Per Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock, adjunctive hydrocortisone therapy showed a 90-day monetized benefit of $8,111 (95% CI, $3,914\u2013$12,307) per patient, driven by improvements in ICU-free days, vasopressor-free days, ventilation-free days, and blood transfusion proportion. The total estimated annual impact of adjunctive hydrocortisone therapy, in 2019 dollars, was $750 million. Per Activated Protein C and Corticosteroids for Human Septic Shock, adjunctive hydrocortisone therapy showed a 90-day monetized benefit of $25,539 per patient (95% CI, $22,853\u2013$28,224), driven by improvements in ICU free-days, vasopressor-free days, and ventilation-free days. The total estimated annual impact of adjunctive hydrocortisone therapy, in 2019 dollars, was $2.3 billion. The deterministic one-way sensitivity analysis showed the cost of ICU stays to be the most influential factor in both analyses. The sensitivity analysis using the reported median showed a greater monetized benefit of $10,658 (Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock) and $30,911 (Activated Protein C and Corticosteroids for Human Septic Shock) per patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Using adjunctive hydrocortisone therapy yields a significant monetized benefit based on inputs from the Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock and Activated Protein C and Corticosteroids for Human Septic Shock trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ccm.0000000000004501","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:00:17Z","timestamp":1595415617000},"page":"e906-e911","source":"Crossref","is-referenced-by-count":2,"title":["Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective"],"prefix":"10.1097","volume":"48","author":[{"given":"Mok","family":"Oh","sequence":"first","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad E.","family":"Patanwala","sequence":"additional","affiliation":[{"name":"The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, NSW, Australia."},{"name":"Royal Prince Alfred Hospital, Sydney, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimer","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaali","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ."},{"name":"Saudi Food and Drug Authority, Riyadh, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ."},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ."},{"name":"Department of Family and Community Medicine, College of Medicine \u2013 Tucson, University of Arizona, Tucson, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Erstad","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ."},{"name":"Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230728","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.1963.63700060029012","article-title":"The effectiveness of hydrocortisone in the management of severe infections.","volume":"183","year":"1963","journal-title":"JAMA"},{"key":"R2-20230728","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s00134-015-3899-6","article-title":"Glucocorticosteroids for sepsis: Systematic review with meta-analysis and trial sequential analysis.","volume":"41","author":"Volbeda","year":"2015","journal-title":"Intensive Care Med"},{"key":"R3-20230728","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016.","volume":"45","author":"Rhodes","year":"2017","journal-title":"Crit Care Med"},{"key":"R4-20230728","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock.","volume":"378","author":"Venkatesh","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20230728","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock.","volume":"378","author":"Annane","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20230728","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations forreporting cost-effectiveness analyses. Panel on cost-effectiveness in healthand medicine.","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"key":"R7-20230728","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R8-20230728","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"R9-20230728","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMe1801463","article-title":"A role for hydrocortisone therapy in septic shock.","volume":"378","author":"Suffredini","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20230728","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.CCM.0000164543.14619.00","article-title":"Daily cost of an ICU day: The contribution of mechanical ventilation.","volume":"33","author":"Dasta","year":"2005","journal-title":"Crit Care Med"},{"key":"R12-20230728","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/MLR.0b013e31817d9342","article-title":"Cost savings attributable to reductions in intensive care unit length of stay for mechanically ventilated patients.","volume":"46","author":"Kahn","year":"2008","journal-title":"Med Care"},{"key":"R13-20230728","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models.","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"R14-20230728","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2017.13836","article-title":"Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014.","volume":"318","author":"Rhee","year":"2017","journal-title":"JAMA"},{"key":"R15-20230728","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/cc9044","article-title":"Global utilization of low-dose corticosteroids in severe sepsis and septic shock: A report from the PROGRESS registry.","volume":"14","author":"Beale","year":"2010","journal-title":"Crit Care"},{"key":"R16-20230728","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.ccx.0000244117.08753.38","article-title":"Understanding economic outcomes in critical care.","volume":"12","author":"Kahn","year":"2006","journal-title":"Curr Opin Crit Care"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T07:53:42Z","timestamp":1690530822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000004501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000004501","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}